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Introduction
Primary graft dysfunction (PGD) is a form of acute lung 
injury (ALI) that occurs within the first few days after 
allograft reperfusion in lung transplant recipients. The 
incidence of PGD is known to be 10–30% and it is the 
major cause of mortality within the first post-transplant year 
(1,2). PGD necessitates prolonged mechanical ventilation 
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and a longer stay in the intensive care unit (ICU), and 
leads to poor functional outcomes and an increased risk 
of bronchiolitis obliterans syndrome (1,2). PGD grade 
3 is associated with worse clinical outcomes than other 
PGD grades regardless of time point (3,4). Therefore, the 
identification of risk factors for PGD, especially PGD grade 
3, is very important for improving the outcomes of lung 
transplantation patients.
Several studies have attempted to identify clinical risk 
factors for PGD after lung transplantation, but have given 
conflicting results, possibly as a result of different sample 
sizes, inconsistencies in PGD definition, and a failure to 
consider multiple clinical factors (4-6). Since 2005, when 
the International Society for Heart and Lung Transplantation 
(ISHLT) published guidelines for PGD, its definition has 
become more consistent, although differences of clinical 
factors associated with PGD between centers can still 
remain (1,4,5,7).
Studies of PGD after lung transplantation are particularly 
limited in Asia, despite the growing use of this procedure, 
and we have therefore sought to identify clinical risk factors 
for PGD and to study the outcomes of PGD in order to 
improve the care of lung transplantation patients in Korea.
Methods
Study design and population
We performed a retrospective study using data collected 
between January 2010 and March 2014 in one tertiary care 
hospital in South Korea. Sixty-one patients aged ≥18 years 
who underwent single or bilateral lung transplantation were 
performed lung transplantation during study period and all 
the patients were enrolled.
Lung transplantation
(I) Method of lung harvesting, preservation solution, 
anterograde and/or retrograde perfusion. All organs 
were recovered en bloc and organ was obtained 
from mechanically assisted brain-dead donors. For 
preservation solution, low-potassium dextran solution 
(Perfadex®; Duraent Biologicals, Hyderabad, India) was 
used. Anterograde and retrograde flushing were used.
(II) Technique of implantation: clamshell incision in 
fourth intercostal space was used in double lung 
transplantation. Anterolateral thoracotomy was 
also used. When double lung transplantation was 
performed, right side organ was usually implanted first.
(III) Criteria for extracorporeal life support (CPB 
vs. ECMO): patients with preoperative ECMO 
underwent surgery with ECMO support,  but 
if the patient could not tolerate with ECMO 
support, CPB was instituted. When the patient was 
hemodynamically unstable or the patient cannot 
tolerate to pulmonary artery clamping or single-lung 
ventilation, CPB was instituted.
Definition of PGD grading
We graded PGD according to the ISHLT criteria, based on 
the partial pressure of oxygen (PaO2)/fraction of inspired 
oxygen (FiO2) ratio and the presence of diffuse parenchymal 
infiltrates in the allograft on a chest radiograph (1,3,8). 
And we diagnosed PGD after excluding other diagnosis. 
As for infection such as pneumonia, clinical situation and 
parameters such as CRP, fever and sputum characteristics 
were used. And to rule out vascular anatomic complication, 
clinical situation was considered and if needed, imaging 
modalities such as ultrasonography was used. The primary 
outcome was the development of grade 3 PGD (PaO2/FiO2 
ratio <200) at 48 or 72 hours after transplantation, and the 
clinical outcome after grade 3 PGD.
Variables
The evaluated factors of recipients were age, gender, body 
mass index (BMI) (kg/m2), preoperative diagnosis, the use 
of extracorporeal membrane oxygenation (ECMO) before 
lung transplantation, echocardiographic parameters before 
lung transplantation, smoking history, transplantation type, 
the use of cardiopulmonary bypass (CPB) during surgery, 
and the intraoperative ischemic time. Ischemic time was 
defined as the ischemic period between the initiation of 
the aorta cross clamp to the start of cold perfusion. The 
clinical data of donors were also evaluated, including age, 
gender, BMI, smoking history, heart function as assessed by 
echocardiography, oxygenation, and duration of ventilator 
use. Participants were classified into five BMI groups 
according to the World Health Organization’s criteria for 
Asia-Pacific populations (9): BMI <18.5, 18.5≤ BMI <23.0, 
23.0≤ BMI <25.0, 25.0≤ BMI <30.0, and 30.0≤ BMI.
Clinical outcome
We evaluated the clinical outcome after PGD which was 
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evaluated by re-operation, postoperative ventilator days, 
postoperative ICU stay, acute kidney injury, need for 
renal replacement therapy (RRT) after transplantation, 
tracheostomy, and postoperative hospital stay. The 
definition of re-operation was the operation which was 
performed after transplantation due to any cause. The 
cause of re-operation included the bleeding, empyema, 
bronchopleural fistula, wound dehiscence and pericardial 
effusion.
Statistical analysis
Data are described as numbers (percentages) or medians 
[interquartile ranges (IQRs)]. We compared variables using 
the Mann-Whitney or Chi-square test. Potential risk factors 
for grade 3 PGD previously identified in the literature 
and shown by univariate analysis in our study or with 
hypothetical clinical or biologic plausibility were selected 
for analysis (1-8,10-18). A logistic regression model was 
used to identify the independent variables associated with 
grade 3 PGD. A two-tailed P value <0.05 was considered 
statistically significant. The PASW Statistics 18 software 
package (IBM, Armonk, New York, USA) was used for all 
analyses.
Ethics
The research protocol was approved by the Institutional 
Review Board (IRB) of Severance Hospital (IRB No. 
4-2013-0770).
Results
A total of 61 patients who received lung transplantation 
were enrolled. A total of 16 subjects (26.2%) met 
criteria for grade 3 PGD at the first 48 or 72 hours after 
transplantation. 
Baseline characteristics of recipients and univariate 
analysis of variables related to recipients stratified by PGD 
status are presented in Table 1. Median age (grade 0–2 PGD 
vs. grade 3 PGD: 52 years, range 21–71 years vs. 53.5 years, 
21–69 years; P=0.544) and the proportion of male patients 
(51.1% vs. 68.7%; P=0.222) were not significantly different 
between the grade 0–2 and grade 3 PGD groups. Idiopathic 
pulmonary fibrosis was the most common diagnosis 
before transplantation in both groups (44.4% vs. 50.0%, 
P=0.734). A higher BMI (median: 19.2, IQR 16.9–21.6 
vs. median: 22.9, IQR 20.1–26.6, P=0.002), any history 
of smoking (13.3% vs. 50.0%, P=0.038), and ECMO use 
before transplantation (13.3% vs. 37.5%, P=0.037) were 
significantly more common in the grade 3 than in the grade 
0–2 PGD group.
The univariate analyses of variables related to the donor 
and operation are summarized in Tables 2 and 3. There 
were no donor-related variables associated with grade 3 
PGD. Age, gender, BMI, smoking history, PaO2/FiO2 ratio 
before transplantation, the duration of ventilator use, the 
type of transplantation, and intraoperative cardiopulmonary 
support were not associated with grade 3 PGD. Only the 
total intraoperative ischemic time was significantly longer in 
the grade 3 PGD group than in the grade 0–2 PGD group 
(median: 350.0 min, IQR 319.0–396.0 min vs. 307.0 min, 
IQR: 283.3–363.3 min, P=0.012).
Multivariate analysis revealed that a high BMI in 
recipients [odds ratio (OR), 1.286; 95% confidence interval 
(CI), 1.008–1.640; P=0.043] and a longer intraoperative 
ischemic time (OR, 1.028; 95% CI, 1.008–1.048; P=0.007) 
were independent risk factors for grade 3 PGD (Table 4).
The outcomes of grade 0–2 and grade 3 PGD patients 
are summarized in Table 5. Grade 3 PGD was significantly 
associated with a higher re-operation rate (grade 0–2 PGD 
vs. grade 3 PGD: 22.2% vs. 50.0%; P=0.036), prolonged 
ventilation (median: 6.0 days, IQR 4.0–18.5 days vs. 
14.5 days, IQR: 8.0–30.0 days; P=0.044), a longer ICU stay 
(median: 9.0 days, IQR: 6.0–24.0 days vs. 17.0 days, 9.5– 
35.0 days; P=0.041), and a higher rate of RRT (17.8% vs. 
62.5%; P=0.001) after transplantation.
Discussion 
In this study, we identified risk factors for grade 3 PGD at 
48 or 72 hours after lung transplantation, and assessed the 
outcome of these patients. A higher BMI in recipients and 
a longer total intraoperative ischemic time were associated 
with grade 3 PGD after lung transplantation, and the 
outcome of grade 3 PGD patients was poorer than that of 
patients with grade 0–2 PGD with respect to the rate of re-
operation, the duration of ventilator treatment, the length 
of ICU stay, and the rate of RRT.
PGD is a rather common complication, occurring in 
10–30% of lung transplant recipients (1,8). Diamond et al. 
found that the incidence of grade 3 PGD varied (2–27%) 
across multiple centers in the US, although a consistent 
definition of PGD was used (5). They concluded that 
the distribution of risk factors, the lack of a standardized 
treatment approach, and differences in patient characteristics 
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Table 1 Baseline characteristics of recipients and univariate analysis of variables related with recipients stratified by PGD status
Variables Total (n=61) PGD 0–2 (n=45) PGD 3 (n=16) P value
Age, median [range] 52 [21–71] 52 [21–71] 53.5 [21–69] 0.544
Gender, male, n (%) 34 (55.7) 23 (51.1) 11 (68.7) 0.222
BMI, kg/m2, median (IQRs) 20.1 (17.6–23.0) 19.2 (16.9–21.6) 22.9 (20.1–26.6) 0.002
BMI by category, n (%) 0.005
<18.5 19 (31.1) 17 (37.8) 2 (12.5)
18.5–23.4 30 (49.2) 22(48.9) 8 (50.0)
23.5–24.9 3 (4.9) 3 (6.7) 0 (0)
25–29.9 9 (14.8) 3 (6.7) 6 (3.6)
>30 0 (0) 0 (0) 0 (0)
ABO 0.903
A 20 (32.8) 15 (33.3) 5 (31.3)
B 19 (31.1) 14 (31.1) 5 (31.3)
AB 5 (8.2) 3 (6.7) 2 (12.5)
O 17 (27.9) 13 (28.9) 4 (25.0)
Transplant type, single, n (%) 6 (9.8) 5 (11.1) 1 (6.3) 0.703
Smoking history, yes, n (%) 12 (19.7) 6 (13.3) 6 (50.0) 0.038
Primary diagnosis, n (%) 0.734
COPD 2 (3.3) 2 (4.4) 0 (0)
IPF 28 (45.9) 20 (44.4) 8 (50.0)
CVD-ILD 5 (8.2) 3 (6.7) 2 (12.5)
LAM 9 (14.8) 7 (15.6) 2 (12.5)
AIP 3 (4.9) 2 (4.4) 1 (6.3)
PPAH 1 (1.6) 1 (2.2) 0 (0)
Destroyed lung 6 (9.8) 4 (8.9) 2 (12.5)
BO after SCT 5 (8.2) 4 (8.9) 1 (6.3)
Other 2 (3.3) 2 (4.4) 0 (0)
ECMO usage before TPL, n (%) 12 (19.7) 6 (13.3) 6 (37.5) 0.037
ECMO duration before TPL (median, IQR) 18 (2.75–27.5) 22.5 (7.0–50.8) 12.0 (2.0–23.0) 0.336
Cardiac catheterization parameter#
mPAP, mean (IQR) 32 (25.0–42.0) 30.0 (23.5–40.0) 36.0 (34.0–47.0) 0.375
Echocardiographic parameters*
LVEF, median (IQR) 65 (60–71) 65.0 (52.7–71.3) 65.5 (57.3–71.0) 0.332
E/E’, median (IQR) 9.5 (7.7–11.8) 10.0 (6.0–12.0) 8.7 (7.8–10.3) 0.962
RVSP, median (IQR) 46.5 (36.3–60) 46.0 (36.3–55.8) 50.6 (35.0–72.2) 0.473
RMWA, yes, n (%) 4 (8.1) 3 (8.1) 1 (8.3) 1.000
#, cardiac catheterization was performed only in 28 recipients in PGD 0–2 group and 7 in PGD 3 group; *, echocardiography was performed 
only in 37 recipients in PGD 0–2 group and 12 in PGD 3 group. PGD, primary graft dysfunction; BMI, body mass index; IQRs, interquartile 
ranges; ABO, ABO blood type; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; CVD-ILD, collagen vascular  
disease related interstitial lung disease; LAM, lymphangioleiomyomatosis; AIP, acute interstitial pneumonia; PPAH, primary pulmonary  
hypertension; BO, bronchiolitis obliterans; SCT, stem cell transplantation; ECMO, extracorporeal membrane oxygenation; TPL, transplantation;  
mPAP, mean pulmonary artery pressure; LVEF, left ventricular ejection fraction; E/E’, ratio of early diastolic trans-mitral flow velocity and mitral 
annular velocity; RVP, right ventricle systolic pressure; RMWA, regional wall motion abnormality.
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Table 2 Univariate analysis of variables related with donors stratified by PGD status
Variables PGD 0–2 (n=45) PGD 3 (n=16) P value 
Age, median [range] 41 [33–51] 43.5 [39–49.5] 0.533
Gender, male, n (%) 32 (71.1) 13 (81.3) 0.432
BMI, kg/m2, median (IQR) 21.8 (19.9–24.0) 22.8 (20.3–26.0) 0.718
Smoking history, yes, n (%) 14 (31.8) 8 (50.0) 0.234
LVEF, median (IQR)* 60.0 (50.8–65.3) 59.5 (54.8–67.8) 0.575
PF ratio, median (IQR) 455.8 (389.8–518.3) 443.6 (361.0–515.5) 0.412
Ventilator using time, hrs, median (IQR) 118.0 (80.8–195.5) 94.5 (62.3–126.3) 0.148
*, data of LVEF was obtained by echocardiography. PGD, primary graft dysfunction; BMI, body mass index; IQRs, interquartile ranges; 
LVEF, left ventricular ejection fraction; PF, PaO2/FiO2.
Table 3 Univariate analysis of variables related with operation stratified by PGD status
Variables PGD 0–2 (n=45) PGD 3 (n=16) P value
TPL type 0.703
Double, n (%) 39 (86.7) 15 (93.8)
Single, n (%) 5 (11.1) 1 (6.3)
Lung-heart TPL, n (%) 1 (2.2) 0 (0)
Cardiopulmonary support during operation 0.071
ECMO, n (%) 26 (57.8) 5 (31.2)
CPB, n (%) 19 (42.2) 11 (68.8)
Total ischemic time, min, median (IQR) 307.0 (283.3–363.3) 350.0 (319.0–396.0) 0.012
PGD, primary graft dysfunction; TPL, transplantation; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; IQR, 
interquartile ranges.
Table 4 Multivariate analysis of variables stratified by PGD status
Variables OR 95% CI P value 
Age, yrs 0.963 0.894–1.037 0.321
Male sex 0.433 0.047–3.987 0.460
BMI, kg/m2 1.286 1.008–1.640 0.043
Recipient smoking history, pyrs 10.311 0.667–159.462 0.095
Preoperative ECMO usage in recipients 6.217 0.807–47.866 0.079
CPB usage during operation (vs. ECMO) 5.026 0.657–38.454 0.067
Donor smoking history, pyrs 0.522 0.096–2.850 0.453
Total ischemic time, min 1.028 1.008–1.048 0.007
PGD, primary graft dysfunction; OR, odds ratio; CI, confidence interval; BMI, body mass index; ECMO, extracorporeal membrane  
oxygenation; TPL, transplantation; CPB, cardiopulmonary bypass.
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may have contributed to this variation. In our study, the 
incidence of grade 3 PGD was 26.2%. Although the total 
number of lung transplantations in Korea is relatively 
small, the incidence of grade 3 PGD was equivalent to that 
reported in some previous studies, suggesting that similar 
factors were associated with grade 3 PGD.
Some studies reported that donor smoking history, 
alcohol consumption, being overweight, a single lung 
transplantation, use of CPB during the operation, 
preoperative medical history of sarcoidosis or pulmonary 
artery hypertension, and higher preoperative mean 
pulmonary artery pressure were risk factors for PGD after 
lung transplantation (1,2,10-13,19). Other studies found 
that female gender and the use of transfusion were risk 
factors for the development of PGD (5,7).
In this study, a higher BMI was significantly associated 
with grade 3 PGD, which concurs with the findings 
of a previous report in which overweight and obese 
patients were enrolled (12). However, because the 
proportion of overweight and obese patients in our study 
was low, caution is required in the interpretation of its 
results. Underweight patients have many problems in 
transplantation, nevertheless, their risk of grade 3 PGD 
tend to be low compared to normal body weight patients 
in our study. Possible mechanisms through which a higher 
BMI increases the risk of grade 3 PGD are leptin-mediated 
lung inflammation and the production of pro-inflammatory 
cytokines from adipose tissues and macrophages (12,20,21).
A longer intraoperative ischemic time was also found 
to be a risk factor for grade 3 PGD in our study. Previous 
studies have had conflicting findings in this respect. Thabut 
and colleagues found that cold ischemic time was associated 
with poor outcomes among patients with PGD (14), 
whilst other groups reported that there was no association 
between ischemic time and PGD (5,8,15,16). There 
could be a threshold ischemic time for the development 
of significant ischemic reperfusion injury, and thus the 
development of PGD might vary between centers that have 
different mean intraoperative ischemic times. However, 
the exact relationship between ischemic time and PGD is 
not fully understood. Future research into these underlying 
mechanisms may lead to improved preventive strategies.
Although not statistically significant in multivariate 
analysis, factors such as smoking history in recipients 
(13.3% vs. 50.0%; P=0.038) and the use of ECMO before 
transplantation (13.3% vs. 37.5%; P=0.037) were associated 
with grade 3 PGD in univariate analysis. Smoking and 
the use of ECMO can induce systemic inflammation and 
ECMO may be related to a poor general condition of the 
recipient. Thus, systemic inflammation or the recipient’s 
general condition may be associated with PGD after 
transplantation.
The outcome of the grade 3 PGD group was poorer 
than that of the grade 0–2 PGD group, in agreement with 
previous studies (5,17,18). Although a longer stay in ICU 
and longer ventilator use in the grade 3 PGD group were 
consistent with other studies, a higher rate of re-operation, 
acute kidney injury, and RRT in grade 3 PGD patients 
has not been reported before. This may be the result of 
severe hypoxia in grade 3 PGD, or possibly the poorer 
condition of recipients as the rate of ECMO usage before 
transplantation was higher in the grade 3 PGD group.
This study had a number of strengths and limitations. 
The strengths includes the fact that this is the first study of 
PGD after lung transplantation in Asia, and our findings 
reveal that the incidence, risk factors, and outcome of 
PGD were relatively similar to those reported by previous 
international reports. Limitations include the use of only 
Table 5 Difference of outcome between PGD 0–2 group and PGD 3 group
Variables PGD 0–2 (n=45) PGD 3 (n=16) P value
Re-operation after TPL, yes, n (%) 10 (22.2) 8 (50.0) 0.036
Postoperative ventilator usage, days, median (IQR) 6.0 (4.0–18.5) 14.5 (8.0–30.0) 0.044
ICU stay after operation, days, median (IQR) 9.0 (6.0–24.0) 17.0 (9.5–35.0) 0.041
AKI, n (%) 24 (53.3) 12 (75.0) 0.013
RRT, n (%) 8 (17.8) 10 (62.5) 0.001
Tracheostomy, n (%) 22 (48.9) 11 (68.8) 0.171
Postoperative hospital stay, days, median (IQR) 31.0 (24.0–66.0) 22.0 (14.5–73.0) 0.231
PGD, primary graft dysfunction; TPL, transplantation; ICU, intensive care unit; AKI, acute kidney injury; RRT, renal replacement therapy; 
IQR, interquartile ranges.
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one center, the potential for bias, and the exclusion of 
factors such as final mortality. Second, we were confused in 
excluding edema and infection from PGD in some patients. 
However, several methods were used to differentiate PGD 
from other conditions. To exclude pneumonia, symptoms 
such as fever or increased sputum, culture, C-reactive 
protein, and response to antibiotics were monitored. 
And echocardiography was routinely used to exclude 
cardiogenic pulmonary edema and pulmonary venous 
outflow obstruction. Third, factors such as intraoperative 
transfusion and elevated mean pulmonary artery pressure 
in donors, which are known risk factors for PGD, were not 
fully analyzed due to limited information. Finally, this study 
was relatively small and retrospective in nature. Further 
prospective studies are needed that include greater patient 
numbers.
In conclusion, we have identified risk factors associated 
with the development of grade 3 PGD and assessed the 
outcome of grade 3 PGD after lung transplantation. 
Patients who developed grade 3 PGD had higher re-
operation rate, longer ventilator apply, longer intensive 
care unit stay, higher rate of RRT, with higher BMI and 
total intraoperative ischemic time being the significant risk 
factor. Our findings could be used to develop predictive 
models to help physicians to modify identifiable risk factors 
prior to the development of PGD.
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